The analysis of lipid metabolism targets related to the de novo lipogenesis (SREBF1, FASN, SCD1) and cholesterogenesis (HMGCR), activation of fatty acids (ACSLs), homeostasis of cholesterol (ABCA1, ApoA1), biosynthesis and remodelling of membrane phospholipids (CHKA, AGPAT), as well as lipid related oncogenic pathways implicated in cell proliferation (EGFR) and inflammation (JAK1), indicated a relevant role of SFRE on the inhibition of lipid metabolism reprogramming in NSCLC cells. Here, SREBF1 is linked to non-small cell lung carcinoma.